Ucb Biopharma Sprl

Ucbbiopharma Srl

Ucb Pharma, S.a.

Celltech Therapeutics Limited

Celltech R&d Limited

Helene Margaret Finney

Kerry Louise Tyson

Alastair David Griffiths Lawson

Stephen Edward Rapecki

Michael John Wright

Terence Seward Baker

Marc Roger De Ryck

Karen Margrete Miller

Christian Gilbert J Wolff

Bryan John Smith

Lara Kevorkian

Paul Alan Atherfold

Kaushik Sarkar

Stevan Graham Shaw

Christoph Meier

Thomas Allen Ceska

Derek Thomas Brown

Hishani Kirby

Alastair David Lawson

Christian Gilbert Wolff

The disclosure relates to antibodies specific to FcRn, formulations comprising the same, use of each in therapy, processes for expressing and optionally formulating said antibody, DNA encoding the antibodies and hosts comprising said DNA.

Anti-FcRn antibodies

The present disclosure relates to antibody molecules comprising a binding domain specific to CD22, said binding domain comprising SEQ ID NO: 1, 2, 3, 4, 5 and 6 or 7. The disclosure also extends to pharmaceutical compositions comprising said antibody molecules and use of the antibody molecules/compositions in treatment.

Antibody molecules which bind CD22

The present disclosure relates to constructs, such as antibody molecules comprising a binding domain specific to CD45, said binding domain comprising SEQ ID NO: 1, 2, 3 and/or SEQ ID NO: 4, 5 and 6. The disclosure also extends to pharmaceutical compositions comprising said constructs and use of the constructs/compositions in treatment.

Antibody molecules which bind CD45

The present disclosure relates to multispecific molecule comprising a binding domain specific to the antigen CD22 and a binding domain specific to the antigen CD79a and/or CD79b, compositions comprising the same and use of both in treatment, for example the treatment of autoimmune disease.

Molecules with specificity for CD79 and CD22

Antibodies specific to FCRN

The present invention is directed to a method of controlling and directing cells, for example to stimulate an immune response, inhibit an immune response, direct tissue regeneration or prevent tissue damage for therapeutic activity through the use of heterodimerically-tethered bispecific protein complex of formula A-X:Y-B. Component A may present X on the surface of a cell, may bind a protein (including a marker) expressed on the surface of an effector cell, or A-X is expressed on the surface of an effector cell, whilst B is specific to an epitope on target cell or tissue of interest. X:Y is a heterodimeric-tether which is formed by a binding interaction between X and Y, which together with A and B assists and effects the controlling and directing of the selected cells.

Method employing bispecific protein complex

The present disclosure relates to a multispecific molecule comprising a binding domain specific to the antigen CD45 and a binding domain specific to the antigen CD79a and/or CD79b, compositions comprising same and use of each in treatment, for example treatment of autoimmune disease.

Molecules with specificity for CD45 and CD79

The present disclosure relates to antibody molecules comprising a binding domain specific to CD79, said binding domain comprising SEQ ID NO: 1, 2, 3 or 4, and/or SEQ ID NO: 5, 6 and 7. The disclosure also extends to pharmaceutical compositions comprising said antibody molecules and use of the antibody molecules/compositions in treatment.

Antibody molecules which bind CD79

The present disclosure relates to a novel bispecific protein complex and a method of using the complexes to screen for synergistic or novel biological function. The bispecific format is particularly suitable for high-throughput screening because all of its components can be expressed from cells as individual units and the units can be assembled simply by mixing without employing conjugation or coupling chemistry.

Bispecific format suitable for use in high-through-put screening

Antibodies specific to FcRn

Growing community of inventors

Slough, United Kingdom

Helene Margaret Finney